Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report

RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary R...

全面介紹

書目詳細資料

發表在:	Frontiers in Oncology
Main Authors:	Caio Abner Leite, Raíssa Pierri Carvalho, Felipe Marques da Costa, Augusto Kreling Medeiros, Fabio Augusto Schutz, William Nassib William
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2023-10-01
主題:	lung adenocarcinoma RET fusion MET amplification selpercatinib capmatinib
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1264231/full